Sir,The study performed by Almangush chooses to focus on Oral Tongue Squamous Cell Carcinoma (OTSCC) alone, though it is clear that comprehensive research studies on molecular markers as prognosticators in OTSCC is sparse. There is a lack of comprehensive meta-analyses and systematic reviews existing in OTSCC and the attempt made by the authors to fill this knowledge gap is highly commendable; however, the study does not fulfil the ideal vision of the authors to identify clinically viable prognostic markers in OTSCC. To achieve this, we must realise that there exists an inherent publication bias if this study limits itself to OTSCC, as the collective pool of research on this subject is already quite low. Therefore, if the primary aim of the study is to be fulfilled, then the horizons of this systematic review and meta-analysis should be expanded to include OSCC as well as other SCC occurring in the mucosal regions of the Head and Neck.We also suggest that if the study was more flexible in its selection criteria to include studies where OTSCC was analysed as a subset of other anatomical sites of HNSCC, considering the histological and molecular similarities between different types of HNSCC including OTSCC, the resulting pool of studies would have been capable of underlining biomarkers having significant prognostic effect in HNSCC as well as OTSCC.As a point of contention, we would like to highlight the promising oncogenic and prognostic marker, eukaryotic translation initiation factor 4E, also known as eIF4E. In cancer, eIF4E overexpression results in cellular growth, angiogenesis, malignancy, transformation, tumourigenesis and metastasis (Zimmer ; Meric-Bernstam, 2008). Overexpression of eIF4E has also been observed in HNC, with previous studies showing up to 100% increase in eIF4E expression in HNC patients (Nathan ; Cardesa and Nadal, 2011). Competitive PCR and IHC analysis have also visualised overexpression of eIF4E in tumour-free surgical margins of HNC (Nathan ), with the respective studies predicting a seven-fold increase in risk of local recurrence (Nathan ).
Authors: Alhadi Almangush; Ilkka Heikkinen; Antti A Mäkitie; Ricardo D Coletta; Esa Läärä; Ilmo Leivo; Tuula Salo Journal: Br J Cancer Date: 2017-07-27 Impact factor: 7.640
Authors: Alhadi Almangush; Ilkka Heikkinen; Antti A Mäkitie; Ricardo D Coletta; Esa Läärä; Ilmo Leivo; Tuula Salo Journal: Br J Cancer Date: 2018-02-15 Impact factor: 7.640
Authors: Lucrezia Togni; Vito Carlo Alberto Caponio; Nicoletta Zerman; Giuseppe Troiano; Khrystyna Zhurakivska; Lorenzo Lo Muzio; Andrea Balercia; Marco Mascitti; Andrea Santarelli Journal: Cancers (Basel) Date: 2022-07-22 Impact factor: 6.575